Recent studies have lent support for a variety of hypotheses explaining the debilitating symptoms affecting millions of people after SARS-CoV-2 infection.
A vaccine strategy involving formulation changes, an initial escalating dose, and a longer wait for booster immunization results in more-effective antibody production against HIV in rhesus monkeys, a study finds.
For the first time, researchers performed a head-to head longitudinal study comparing the immune response elicited by mRNA and traditional COVID-19 vaccines to primary infections.
Alejandra Manjarrez, PhD | May 6, 2022 | 4 min read
Compared to mice who got the doses in separate limbs, animals receiving flu shots in the same paw for both a first and second dose had better-trained memory B cells that bound tighter to the vaccine antigen.
A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.
Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.
Commerically-available peripheral blood mononuclear cells offer a well-characterized, accessible, and consistent model for immunology and therapeutic development.